• Explore /
  • Poster
  • / Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).

Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).

Abstract Poster

Authors

null

Rodabe Navroze Amaria

The University of Texas - MD Anderson Cancer Center, Houston, TX

Rodabe Navroze Amaria , Cara L. Haymaker , Marie-Andree Forget , Roland Bassett , Janice N. Cormier , Michael A. Davies , Adi Diab , Jeffrey E. Gershenwald , Isabella Claudia Glitza , Jeffrey Edwin Lee , Anthony Lucci , Jennifer Leigh McQuade , Sapna Pradyuman Patel , Richard Eldon Royal , Merrick I. Ross , Hussein Abdul-Hassan Tawbi , Jennifer Ann Wargo , Michael K.K. Wong , Chantale Bernatchez , Patrick Hwu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02500576

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9543)

DOI

10.1200/JCO.2019.37.15_suppl.9543

Abstract #

9543

Poster Bd #

114

Abstract Disclosures

Similar Posters

First Author: Jason Alan Chesney

First Author: Rodabe Navroze Amaria

First Author: Rodabe Navroze Amaria

First Author: Amod Sarnaik